Top MarketRank™ StocksTop MarketRank™NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $84.08 -1.04 (-1.22%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$83.73▼$86.0450-Day Range$80.47▼$93.8452-Week Range$73.68▼$99.56Volume1.58 million shsAverage Volume1.84 million shsMarket Capitalization$15.97 billionP/E Ratio78.58Dividend YieldN/APrice Target$106.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside26.2% Upside$106.10 Price TargetShort InterestHealthy3.50% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.54Based on 36 Articles This WeekInsider TradingN/AProj. Earnings Growth31.91%From $2.35 to $3.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.95 out of 5 starsMedical Sector10th out of 910 stocksPharmaceutical Preparations Industry4th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 14 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.50% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 3.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.1 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 36 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search Interest11 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows3 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 31.91% in the coming year, from $2.35 to $3.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 78.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.02.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 78.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.16.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesSeptember 7 at 4:55 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $95.00September 7 at 4:21 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $122.00 at Piper SandlerSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 7 at 3:45 AM | americanbankingnews.comTraders Purchase Large Volume of Put Options on BioMarin Pharmaceutical (NASDAQ:BMRN)September 6 at 4:32 PM | markets.businessinsider.comBuy Rating Affirmed for BioMarin Pharmaceutical Amid Strong Voxzogo Outlook and Strategic Growth InitiativesSeptember 6 at 6:57 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $118.00September 6 at 6:24 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Given New $120.00 Price Target at JPMorgan Chase & Co.September 6 at 6:24 AM | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Given "Sector Perform" Rating at Royal Bank of CanadaSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 5 at 8:53 PM | bizjournals.comBioMarin outlines plan to move 'global support functions' to lower-cost areaSeptember 5 at 3:52 PM | markets.businessinsider.comBioMarin Pharmaceutical (BMRN) Gets a Buy from Truist FinancialSeptember 5 at 10:50 AM | benzinga.comBioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027September 5 at 5:49 AM | marketwatch.comBioMarin Pharmaceutical Sees FY27 Revenue $4B, Updates Corporate StrategySeptember 5 at 5:49 AM | marketwatch.comBioMarin Sees FY27 Revenue $4B, Updates Corporate Strategy -- UpdateSeptember 5 at 5:49 AM | msn.comBioMarin plans $500M cost transformation to improve marginsSeptember 5 at 5:49 AM | bizjournals.comBioMarin's refined strategy: More sales, lower costs equals more flexibility for dealsSeptember 4 at 1:00 PM | prnewswire.comBioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial GuidanceSeptember 4 at 7:30 AM | prnewswire.comBioMarin to Host Investor Day Today at 10:30 a.m. Eastern TimeSee More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$106.10 High Stock Price Target$122.00 Low Stock Price Target$72.00 Potential Upside/Downside+26.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$1.07 Trailing P/E Ratio78.58 Forward P/E Ratio35.78 P/E GrowthN/ANet Income$167.65 million Net Margins9.91% Pretax Margin11.54% Return on Equity6.91% Return on Assets5.07% Debt Debt-to-Equity Ratio0.11 Current Ratio3.05 Quick Ratio1.95 Sales & Book Value Annual Sales$2.59 billion Price / Sales6.17 Cash Flow$1.65 per share Price / Cash Flow50.98 Book Value$27.84 per share Price / Book3.02Miscellaneous Outstanding Shares189,880,000Free Float186,367,000Market Cap$15.97 billion OptionableOptionable Beta0.32 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Alexander Hardy (Age 55)President, CEO & Director Comp: $1.72MMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.07MDr. C. Greg Guyer Ph.D. (Age 62)Executive VP & Chief Technical Officer Comp: $1.11MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.1MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.41MMs. Erin Burkhart (Age 45)Group VP & Chief Accounting Officer Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVASarepta TherapeuticsNASDAQ:SRPTMyoKardiaNASDAQ:MYOKReata PharmaceuticalsNASDAQ:RETAMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 22,043 shares on 9/5/2024Ownership: 0.012%Clearbridge Investments LLCSold 1,529 shares on 8/27/2024Ownership: 0.137%Teachers Retirement System of The State of KentuckyBought 28,837 shares on 8/26/2024Ownership: 0.102%Novo Holdings A SBought 40,000 shares on 8/20/2024Ownership: 0.258%Creative PlanningBought 524 shares on 8/16/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $96.42 at the start of the year. Since then, BMRN shares have decreased by 12.8% and is now trading at $84.08. View the best growth stocks for 2024 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings results on Monday, August, 5th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.39. The biotechnology company had revenue of $712.03 million for the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 6.91% and a net margin of 9.91%. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's top institutional shareholders include Primecap Management Co. CA (9.90%), Avoro Capital Advisors LLC (2.40%), Dimensional Fund Advisors LP (0.54%) and DNB Asset Management AS (0.54%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, George Eric Davis, Charles Greg Guyer, V Bryan Lawlis, Erin Burkhart, Mark J Alles and Dennis Slamon. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and Micron Technology (MU). This page (NASDAQ:BMRN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
